Researchers from the University of Missouri School of Medicine have discovered a specific combination immunotherapy that shows promise in the fight against liver cancer.
The therapy involves a tumour-suppressing lipid molecule called nanoliposome C6-ceramide (LipC6) and an antibody for cytotoxic T-lymphocyte antigen 4 (CTLA4).
When used together in this study, LipC6 and the anti- CTLA4 antibody significantly slowed tumour growth and enhanced the strength of tumour-attacking T cells.
“Our analysis revealed the combination therapy significantly extended the life span of tumour-bearing mice compared to the mice with a single type of therapy or no therapy at all,” said co-principal investigator Guangfu Li, PhD, DVM, associate professor in the Department of Surgery and Department of Molecular Microbiology and Immunology.
Li said this finding is especially promising given the current lack of effective therapies against liver cancer, which is the third-leading cause of cancer-related deaths in the U.S.
For patients diagnosed with liver cancer, the average five-year survival rate of all stages is 20%, according to the American Cancer Society.
“What is particularly notable is that we have now demonstrated that LipC6 treatment significantly improves the ability of anti-CTLA-4 antibodies to suppress liver cancer,” Li said. “LipC6 and anti-CTLA-4 antibody have been approved by the FDA to use in human patients, so this combination treatment can be quickly translated to clinical application.”
More research will be required to better understand the underlying mechanisms behind the success of this combination.
“The human therapeutic response to another commonly used type of immunotherapy, anti-PD-1, is only about 14% in liver cancer patients,” said co-principal investigator Kevin F. Staveley-O’Carroll, MD, PhD, professor in the Department of Surgery. “We also tested anti-PD-1 immunotherapy in combination with LipC6, but it showed no benefit compared to the robust response demonstrated by the combination of LipC6 and anti-CTLA4 antibodies. This represents a new and powerful therapeutic approach.”
In addition to Li and Staveley-O' Carroll, other MU co-authors include Xiaoqiang Qi, PhD, research assistant professor; Feng Wu, PhD, post-doctoral fellow; Jussuf Kaifi, MD, assistant professor of surgery; Eric Kimchi, MD, chief of the Division of Surgical Oncology and General Surgery; and Sung Hoon Kim, visiting Scholar from South Korea.
Their study, “Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumour immunity in hepatocellular cancer,” was recently published by the journal Federation of American Societies to Experimental Biology. Research reported in this publication was supported by a grant from the National Institutes of Health’s National Cancer Institute.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.
Highlighting the promise of personalised health care and the impact of large-scale interdisciplinary collaboration, the NextGen Precision Health initiative is bringing together innovators from across the University of Missouri and the UM System’s three other research universities in pursuit of life-changing precision health advancements.
It’s a collaborative effort to leverage the research strengths of Mizzou toward a better future for the health of Missourians and beyond.
The Roy Blunt NextGen Precision Health building at MU anchors the overall initiative and expands collaboration between researchers, clinicians and industry partners in the state-of-the-art research facility.
Source: University of Missouri-Columbia